1. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies

   • Akira I. Hida
   • Yasuaki Sagara
   • Yasuyo Ohi

   Preclinical study Open access 03 June 2016 Pages: 1 - 9

   

2. Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining

   • Rasmus Røge
   • Rikke Riber-Hansen
   • Mogens Vyberg

   Preclinical study 09 June 2016 Pages: 11 - 19

   

3. Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression

   • Yanhong Zhang
   • Adam L. Liss
   • Celina G. Kleer

   Preclinical study 11 June 2016 Pages: 21 - 28

   

4. Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention

   • Justin A. Colacino
   • Sean P. McDermott
   • Laura S. Rozek

   Preclinical study 15 June 2016 Pages: 29 - 41

   

5. Aberrant nocturnal cortisol and disease progression in women with breast cancer

   • Jamie M. Zeitzer
   • Bita Nouriani
   • David Spiegel

   Preclinical study 17 June 2016 Pages: 43 - 50

   

6. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)

   • K. Matter-Walstra
   • T. Ruhstaller
   • K. J. Dedes

   Clinical trial 08 June 2016 Pages: 51 - 57

   

7. Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients

   • Alexander Hein
   • Paul Gass
   • Sara Y. Brucker

   Clinical trial 09 June 2016 Pages: 59 - 65

8. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer

   • Banu K. Arun
   • Yun Gong
   • Nour Sneige

   Clinical trial 10 June 2016 Pages: 67 - 77

   

9. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer

   • Martha Hickey
   • Jennifer L. Marino
   • Swee Wong

   Clinical trial 15 June 2016 Pages: 79 - 90

   

10. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

    • L. M. Smyth
    • N. M. Iyengar
    • C. T. Dang

    Clinical Trial 15 June 2016 Pages: 91 - 97

    

11. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

    • Sasagu Kurozumi
    • Mary Padilla
    • Hiroaki Nitta

    Clinical trial Open access 18 June 2016 Pages: 99 - 111

    

12. Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians

    • Tulay Koru-Sengul
    • Ana M. Santander
    • Marta Torroella-Kouri

    Epidemiology 09 June 2016 Pages: 113 - 126

    

13. A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL)

    • Alfred I. Neugut
    • Grace Clarke Hillyer
    • Dawn L. Hershman

    Epidemiology 10 June 2016 Pages: 127 - 138

    

14. Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ

    • Shi-Yi Wang
    • Jessica B. Long
    • Cary P. Gross

    Epidemiology 10 June 2016 Pages: 139 - 148

    

15. Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses’ Health Study and Nurses’ Health Study II

    • Kelly A. Hirko
    • Renée T. Fortner
    • A. Heather Eliassen

    Epidemiology 13 June 2016 Pages: 149 - 155

16. Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women

    • Lital Keinan-Boker
    • Hagai Levine
    • Jeremy D. Kark

    Epidemiology 15 June 2016 Pages: 157 - 167

    

17. The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases

    • Hanna Dillekås
    • Romano Demicheli
    • Oddbjørn Straume

    Epidemiology Open access 15 June 2016 Pages: 169 - 178

    

18. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study

    • Shusma C. Doebar
    • Esther C. van den Broek
    • Carolien H. M. van Deurzen

    Epidemiology Open access 18 June 2016 Pages: 179 - 187

19. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer

    • Shruti R. Tiwari
    • Prasun Mishra
    • Alberto J. Montero

    Brief Report 20 June 2016 Pages: 189 - 193

    

20. Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

    • Brennan McCullar
    • Manjari Pandey
    • Michael G. Martin

    Brief Report 21 June 2016 Pages: 195 - 202